Companion diagnostic (CDx) tests play a critical role in personalising care by identifying optimal targeted therapies for patients based on their cancer’s unique genetic profile. The Food & Drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...

First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), United States, 15 September 2025 – Biocartis ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician ...

SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary ...

BOSTON, July 14, 2025 /PRNewswire/ -- CDX Medical Technologies (CDX), a pioneer in extracorporeal membrane oxygenation (ECMO) pump innovation, today announced the successful close of its $2.5 million ...

Investing.com -- The Markit CDX North American Investment Grade Index, which is a measure of credit risk using a selection of credit default swaps, reached its highest point since November 2023 on ...

NuMark Credit Union is buying troubled Lemont National Bank in a deal that will boost its presence in the southwestern suburbs. Financial terms of the acquisition, expected to close in the second half ...

NuMark Credit Union in Joliet, Illinois, said Wednesday it would acquire a neighboring Chicago-area bank. The deal picks up on a well-established trend of credit unions buying banks, which has fallen ...

The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, 2025. The FDA has accepted and granted priority review to the biologics ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...